公开(公告)号：US10736692B2

公开(公告)日：2020-08-11

申请号：US15194303

申请日：2016-06-27

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Garrett Pilcher ,  Robert Melder

IPC: A61B18/14 ,  A61N7/02 ,  A61N1/00 ,  A61N1/36 ,  A61B5/00 ,  A61N1/05 ,  A61N7/00 ,  A61B18/00 ,  A61B90/00 ,  A61B18/02 ,  A61B18/18 ,  A61B18/24

Abstract: Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the target sympathetic nerve.

公开(公告)号：US20170312021A1

公开(公告)日：2017-11-02

申请号：US15194303

申请日：2016-06-27

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Garrett Pilcher ,  Robert Melder

IPC: A61B18/14 ,  A61N1/05 ,  A61B5/00 ,  A61B18/02 ,  A61B18/00 ,  A61B18/18 ,  A61N7/00 ,  A61B18/24

CPC classification number: A61B18/1492 ,  A61B5/40 ,  A61B5/4035 ,  A61B18/02 ,  A61B18/1815 ,  A61B18/24 ,  A61B2018/00434 ,  A61B2018/00511 ,  A61B2018/00547 ,  A61B2018/00559 ,  A61B2018/00577 ,  A61B2018/00642 ,  A61B2018/0212 ,  A61B2018/1861 ,  A61B2090/374 ,  A61B2090/376 ,  A61B2090/378 ,  A61N1/00 ,  A61N1/0551 ,  A61N1/36002 ,  A61N7/00 ,  A61N7/02 ,  A61N7/022 ,  A61N2007/0043

Abstract: Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the target sympathetic nerve.

公开(公告)号：US20150327924A1

公开(公告)日：2015-11-19

申请号：US14713604

申请日：2015-05-15

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Robert Melder ,  Martin Rothman ,  Stefan Tunev

IPC: A61B18/14

CPC classification number: A61B18/1492 ,  A61B18/082 ,  A61B18/24 ,  A61B2018/00214 ,  A61B2018/00261 ,  A61B2018/00285 ,  A61B2018/00404 ,  A61B2018/00434 ,  A61B2018/00511 ,  A61B2018/00577 ,  A61B2018/1435 ,  A61B2018/1475 ,  A61B2018/1861 ,  A61N7/022

Abstract: Methods for treating a patient using therapeutic renal neuromodulation and associated devices, system, and methods are disclosed herein. One aspect of the present technology is directed to neuromodulating nerve tissue in selected anatomical regions. In one embodiment, the method can include intravascularly advancing an elongate shaft of a catheter to renal vasculature of a human patient and locating a first neuromodulation element of the catheter within a distalmost portion of a main renal artery. The method includes locating a second neuromodulation element of the catheter within a branch vessel of the renal artery distal to a bifurcation at a distal end of the main renal artery. Neuromodulation of the nerve tissue surrounding the selected anatomical treatment locations can inhibit sympathetic neural activity in nerves proximate a portion of a renal artery and/or a renal branch artery proximate a renal parenchyma.

Abstract translation: 本文公开了使用治疗性肾神经调节和相关装置，系统和方法治疗患者的方法。 本技术的一个方面是针对选择的解剖区域中的神经调节神经组织。 在一个实施例中，该方法可以包括将导管的细长轴血管内推进到人类患者的肾血管，并将导管的第一神经调节元件定位在主肾动脉的最远部分内。 该方法包括将导管的第二神经调节元件定位在远端主肾动脉末端的分叉处的肾动脉分支血管内。 围绕选择的解剖治疗位置的神经组织的神经调节可抑制靠近肾实质部分的肾动脉和/或肾分支动脉附近的神经中的交感神经活动。

公开(公告)号：US20220280230A1

公开(公告)日：2022-09-08

申请号：US17824701

申请日：2022-05-25

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Garrett Pilcher ,  Robert Melder

IPC: A61B18/14 ,  A61N7/02 ,  A61N1/00 ,  A61N1/36 ,  A61B5/00 ,  A61N1/05 ,  A61N7/00

Abstract: Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the target sympathetic nerve.

公开(公告)号：US20190231420A1

公开(公告)日：2019-08-01

申请号：US16271742

申请日：2019-02-08

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Robert Melder ,  Martin Rothman ,  Stefan Tunev

IPC: A61B18/14

CPC classification number: A61B18/1492 ,  A61B18/082 ,  A61B18/24 ,  A61B2018/00214 ,  A61B2018/00261 ,  A61B2018/00285 ,  A61B2018/00404 ,  A61B2018/00434 ,  A61B2018/00511 ,  A61B2018/00577 ,  A61B2018/1435 ,  A61B2018/1475 ,  A61B2018/1861 ,  A61N7/022

Abstract: Methods for treating a patient using therapeutic renal neuromodulation and associated devices, system, and methods are disclosed herein. One aspect of the present technology is directed to neuromodulating nerve tissue in selected anatomical regions. In one embodiment, the method can include intravascularly advancing an elongate shaft of a catheter to renal vasculature of a human patient and locating a first neuromodulation element of the catheter within a distalmost portion of a main renal artery. The method includes locating a second neuromodulation element of the catheter within a branch vessel of the renal artery distal to a bifurcation at a distal end of the main renal artery. Neuromodulation of the nerve tissue surrounding the selected anatomical treatment locations can inhibit sympathetic neural activity in nerves proximate a portion of a renal artery and/or a renal branch artery proximate a renal parenchyma.

公开(公告)号：US20230181251A1

公开(公告)日：2023-06-15

申请号：US18163615

申请日：2023-02-02

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Robert Melder ,  Martin Rothman ,  Stefan Tunev

IPC: A61B18/14

CPC classification number: A61B18/1492 ,  A61B2018/00214

Abstract: Methods for treating a patient using therapeutic renal neuromodulation and associated devices, system, and methods are disclosed herein. One aspect of the present technology is directed to neuromodulating nerve tissue in selected anatomical regions. In one embodiment, the method can include intravascularly advancing an elongate shaft of a catheter to renal vasculature of a human patient and locating a first neuromodulation element of the catheter within a distalmost portion of a main renal artery. The method includes locating a second neuromodulation element of the catheter within a branch vessel of the renal artery distal to a bifurcation at a distal end of the main renal artery. Neuromodulation of the nerve tissue surrounding the selected anatomical treatment locations can inhibit sympathetic neural activity in nerves proximate a portion of a renal artery and/or a renal branch artery proximate a renal parenchyma.

公开(公告)号：US11350992B2

公开(公告)日：2022-06-07

申请号：US16944499

申请日：2020-07-31

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Garrett Pilcher ,  Robert Melder

IPC: A61B18/14 ,  A61N7/02 ,  A61N1/00 ,  A61N1/36 ,  A61B5/00 ,  A61N1/05 ,  A61N7/00 ,  A61B18/00 ,  A61B90/00 ,  A61B18/02 ,  A61B18/18 ,  A61B18/24

Abstract: Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the target sympathetic nerve.